Immuron trots forward on expectations Travelan can 'save private Ryan'

Wed 12 Jan 22, 2:35pm (AEST)
drug pharma pills health care

Share article

Key Points

  • Infectious diarrhoea is the most common illness reported in US troops
  • Clinical studies have already proved that Travelan conferred 84% to over 90% protective efficacy
  • 60 ‘healthy’ volunteers will be tested

Smallcap biopharma company, Immuron Ltd (ASX: IMC) was up 29% two hours out from the close today following revelations the company has received $6.2m to clinically evaluate a military strength dosing regimen for Travelan, a drug for travellers with diarrhoea.

The US Department of Defence has decided to stump up with $4.8m to fund the research, and the US Naval Medical Research Centre (NMRC) received $1.4m to support the study.

Funds will be used to conduct controlled human infection model (CHIM) clinical trials. Around 60 ‘healthy’ volunteers in the US will be tested to confirm the efficacy of a single larger dose regimen of Travelan using the enterotoxigenic Escherichia coli (ETEC) strain H10407.

Will a daily dose do the trick?

While infectious diarrhoea is the most common illness reported in US troops deployed overseas, the current three dose per day regime is said to have low compliance among military personnel.

As a result, trials will attempt to establish whether a single dosing regime could be more appropriate for use in military populations.

Two company sponsored clinical studies have already proved that Travelan conferred 84% to over 90% protective efficacy against moderate to severe diarrhoea upon challenge with ETEC in comparison to a placebo.

Phase 3 registration trials

Results of this clinical study are expected to inform dosing in the pivotal Phase 3 registration trials for BLA licensure.

“The NMRC plans to clinically evaluate the protective efficacy of our new oral therapeutic targeting Campylobacter and ETEC this year in two controlled human infection-model clinical trials,” said Immuron’s CEO Dr Jerry Kanellos

One trial focuses on the ability of the hyperimmune product to protect volunteers against moderate to severe campylobacteriosis, and the second trial focusing on ETEC infections.

Consensus does not cover this stock.

Based on Morningstar’s (29 December 2021) fair value of $0.30 the stock looks to be to marginally undervalued, but investors should not, this predates today’s announcement.


Written By

Mark Story


Mark is an investigative financial journalist and editor who started his career working for Marathon Oil in London. He has a degree in politics/economics and a diploma in journalism. Mark has worked on 70-plus newspapers and financial publications across Australia, NZ, the US, and Asia including: The Australian Financial Review, Money Magazine, Australian Property Investor and Finance Asia. Mark is passionate about improving the financial literacy of all Australians through the highest quality content. Email Mark at [email protected].

Get the latest news and media direct to your inbox

Sign up FREE